US · AVIR
Atea Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boston, MA 02110
- Website
- ateapharma.com
Price · as of 2024-12-31
$5.58
Market cap 365.63M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $67.86 | ||||
| 2021 | $5.79 | $173.72 | $13.90 | $15.89 | $883.05 |
| 2022 | $3.34 | $33.12 | |||
| 2023 | $4.00 | ||||
| 2024 | $2.99 |
AI valuation
Our deep-learning model estimates Atea Pharmaceuticals, Inc.'s (AVIR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.58
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AVIR | Atea Pharmaceuticals, Inc… | $5.58 | 365.63M | — | — | — | — | -1.50 | 0.57 | — | 1.53 | -6.59 | 0.57 | 0.00% | — | — | -33.88% | 1111.34% | -31.78% | 0.00 | — | 24.85 | 24.44 | 0.48 | 2270.00% | — | 5867.00% | -53.78% | -7.28 | 780.43% | 0.00% | 0.00% | 0.00% | 1.04 | 1.48 | — | 4.54 |
| ACHV | Achieve Life Sciences, In… | $4.56 | 242.75M | — | — | — | — | -2.53 | 4.82 | — | -2.04 | — | 5.33 | 0.00% | — | — | -409.51% | 2085.90% | -137.33% | 0.48 | -17.92 | 5.46 | 5.14 | 0.07 | -1733.00% | — | 2151.00% | -29.56% | -4.46 | 1589.43% | 0.00% | 0.00% | 3.93% | -1.95 | -2.56 | — | -6.45 |
| ALLO | Allogene Therapeutics, In… | $2.78 | 624.75M | +924% | -60% | — | +3,007% | -1.65 | 1.01 | 19304.10 | -0.92 | — | 1.01 | 100.00% | -1241813.64% | -1170863.64% | -55.13% | -144.12% | -43.24% | 0.21 | -1509.39 | 8.54 | 8.29 | -0.06 | -3684.00% | -7684.00% | -1599.00% | -47.33% | -5.64 | -106.03% | 0.00% | 0.00% | 0.00% | -0.82 | -1.11 | 10135.01 | -3.69 |
| ARCT | Arcturus Therapeutics Hol… | $8.23 | 233.85M | +247% | -10% | — | +29% | -4.85 | 1.63 | 2.84 | -2.38 | -2.89 | 1.63 | 100.00% | -69.13% | -58.49% | -31.16% | -388.69% | -20.93% | 0.12 | — | 4.67 | 3.68 | 2.69 | 16786.00% | -1227.00% | 18760.00% | -15.37% | -0.91 | -245.39% | 0.00% | 0.00% | 0.00% | -1.93 | -3.05 | 1.33 | 0.78 |
| ENTA | Enanta Pharmaceuticals, I… | $14.30 | 332M | +189% | -59% | — | — | -3.80 | 4.81 | 4.77 | -4.57 | — | 4.81 | 92.98% | -130.65% | -125.36% | -84.63% | -91.13% | -24.91% | 3.11 | -11.11 | 4.21 | 4.03 | -2.38 | -2993.00% | -342.00% | -6674.00% | -10.33% | -0.40 | -35.04% | 0.00% | 0.00% | 6.44% | -3.79 | -10.06 | 4.96 | -1.26 |
| HUMA | Humacyte, Inc. | $1.12 | 159.24M | — | — | — | — | -2.46 | -6.95 | — | -2.55 | -13.86 | -6.95 | 0.00% | — | — | 760.17% | 252.76% | -111.77% | -0.31 | -12.33 | 2.40 | 2.25 | 0.21 | 1776.00% | — | 3190.00% | -27.23% | -4.92 | 220.27% | 0.00% | 0.00% | 1.48% | -2.95 | -3.39 | — | -8.31 |
| PYXS | Pyxis Oncology, Inc. | $1.47 | 91.53M | — | — | — | — | -0.88 | 0.56 | 4.20 | 0.59 | — | 0.57 | 97.06% | -554.07% | -478.95% | -62.75% | -416.82% | -46.74% | 0.17 | — | 7.49 | 7.18 | -0.01 | -2865.00% | — | -2522.00% | -85.42% | -3.26 | -277.36% | 0.00% | 0.00% | 16.14% | 0.44 | 0.67 | -2.41 | -3.02 |
| TRDA | Entrada Therapeutics, Inc… | $11.93 | 455.96M | +114% | -46% | — | +2,115% | -3.36 | 1.58 | 19.01 | -1.67 | — | 1.58 | 83.89% | -621.13% | -565.48% | -39.13% | -244.32% | -31.81% | 0.17 | — | 12.53 | 12.09 | 0.28 | -30655.00% | -8794.00% | 18973.00% | -26.81% | -5.26 | -200.46% | 0.00% | 0.00% | 0.10% | -1.51 | -1.84 | 9.38 | 2.64 |
| VNDA | Vanda Pharmaceuticals Inc… | $8.91 | 526.65M | +158% | -50% | — | — | -2.18 | 1.47 | 2.23 | -1.65 | -0.20 | 2.29 | 93.96% | -69.95% | -102.02% | -50.93% | -119.87% | -38.51% | 0.04 | — | 2.39 | 2.19 | 0.52 | 106875.00% | 872.00% | 57976.00% | -22.94% | -0.75 | -87.57% | 0.00% | 0.00% | 0.00% | -1.52 | -2.08 | 1.07 | 0.57 |
| VYGR | Voyager Therapeutics, Inc… | $4.10 | 227.96M | +883% | -19% | — | +1,465% | -3.78 | 0.82 | 3.07 | -0.29 | — | 0.82 | 100.00% | -104.11% | -81.25% | -24.25% | -162.45% | -17.47% | 0.15 | — | 5.56 | 5.45 | 0.35 | -13805.00% | -6800.00% | -12522.00% | -7.67% | -0.31 | -36.73% | 0.00% | 0.00% | 0.00% | -0.27 | -1.21 | 0.28 | 0.62 |
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- CEO
- Jean-Pierre Sommadossi
- Employees
- 56
- Beta
- 0.23
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.58) − 1 = — (DCF, example).